Anhui Fengyuan Pharmaceutical Past Earnings Performance
Past criteria checks 2/6
Anhui Fengyuan Pharmaceutical has been growing earnings at an average annual rate of 18.9%, while the Pharmaceuticals industry saw earnings growing at 10.3% annually. Revenues have been growing at an average rate of 7.6% per year. Anhui Fengyuan Pharmaceutical's return on equity is 8%, and it has net margins of 3.8%.
Key information
18.9%
Earnings growth rate
17.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 7.6% |
| Return on equity | 8.0% |
| Net Margin | 3.8% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Anhui Fengyuan Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 4,190 | 160 | 742 | 65 |
| 31 Dec 23 | 4,275 | 159 | 782 | 77 |
| 30 Jun 23 | 4,331 | 159 | 876 | 86 |
| 31 Mar 23 | 4,222 | 163 | 887 | 78 |
| 31 Dec 22 | 4,004 | 154 | 851 | 65 |
| 30 Sep 22 | 3,959 | 170 | 802 | 60 |
| 30 Jun 22 | 3,867 | 158 | 797 | 60 |
| 31 Mar 22 | 3,777 | 133 | 824 | 64 |
| 01 Jan 22 | 3,652 | 123 | 818 | 76 |
| 30 Sep 21 | 3,514 | 123 | 843 | 77 |
| 30 Jun 21 | 3,487 | 110 | 879 | 92 |
| 31 Mar 21 | 3,450 | 110 | 896 | 94 |
| 31 Dec 20 | 3,321 | 104 | 916 | 75 |
| 30 Sep 20 | 3,279 | 76 | 973 | 87 |
| 30 Jun 20 | 3,248 | 82 | 1,016 | 72 |
| 31 Mar 20 | 3,223 | 86 | 999 | 75 |
| 31 Dec 19 | 3,238 | 81 | 1,009 | 78 |
| 30 Sep 19 | 3,168 | 80 | 1,039 | 52 |
| 30 Jun 19 | 3,106 | 79 | 999 | 68 |
| 31 Mar 19 | 3,051 | 66 | 1,000 | 71 |
| 31 Dec 18 | 3,013 | 61 | 953 | 73 |
| 30 Sep 18 | 3,018 | 61 | 870 | 95 |
| 30 Jun 18 | 2,894 | 60 | 735 | 91 |
| 31 Mar 18 | 2,765 | 67 | 713 | 11 |
| 31 Dec 17 | 2,578 | 65 | 585 | 60 |
| 30 Sep 17 | 2,474 | 63 | 487 | 25 |
| 30 Jun 17 | 2,302 | 63 | 487 | 0 |
| 31 Mar 17 | 2,133 | 49 | 449 | 0 |
| 31 Dec 16 | 2,034 | 46 | 427 | 0 |
| 30 Sep 16 | 1,731 | 43 | 373 | 0 |
| 30 Jun 16 | 1,673 | 41 | 361 | 0 |
| 31 Mar 16 | 1,585 | 32 | 339 | 0 |
| 31 Dec 15 | 1,569 | 35 | 342 | 0 |
| 30 Sep 15 | 1,623 | 40 | 363 | 0 |
| 30 Jun 15 | 1,640 | 43 | 366 | 0 |
| 31 Mar 15 | 1,693 | 43 | 368 | 0 |
| 31 Dec 14 | 1,699 | 41 | 362 | 0 |
| 30 Sep 14 | 1,694 | 41 | 359 | 0 |
| 30 Jun 14 | 1,664 | 34 | 346 | 0 |
| 31 Mar 14 | 1,585 | 29 | 342 | 0 |
| 31 Dec 13 | 1,530 | 27 | 334 | 0 |
| 30 Sep 13 | 1,425 | 25 | 338 | 0 |
| 30 Jun 13 | 1,439 | 20 | 340 | 0 |
Quality Earnings: 000153 has high quality earnings.
Growing Profit Margin: 000153's current net profit margins (3.8%) are lower than last year (3.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 000153's earnings have grown by 18.9% per year over the past 5 years.
Accelerating Growth: 000153's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 000153 had negative earnings growth (-1.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (8.5%).
Return on Equity
High ROE: 000153's Return on Equity (8%) is considered low.